Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institute of Mental Health (NIMH) · NIH Institute/Center · RFA-MH-27-135
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $5.5M total
- DeadlineFinal application due date.
- Oct 11, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- R01
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 5
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- One-time
- Open dateWhen applications open (or opened).
- Apr 29, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $5.5M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Required
Funding context
Based on FY2025 NIMH R01 applications (194 of 1,956 applications awarded).
Payline: NIH discontinued percentile paylines for 2026 under its Unified Funding Strategy ↗ — scores are now weighed in context rather than against a fixed cutoff.
NIMH R01, FY2025 — atypical NIH funding year (multi-year upfront funding / rescinded paylines); NIH reports FY2025 success rates as not comparable to prior years.
Aggregate historical data by institute, mechanism, and fiscal year — context for planning, not a prediction for this opportunity. Source ↗
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.